MultiCell Technologies Inc. (MCET.OB) Awarded European Patent for Candidate Targeting Cancer
MultiCell Technologies Inc. engages in the development and commercialization of breakthrough therapeutics, and has a portfolio of new drug candidates and patented drug development technology platforms. The company today announced it has received European patent covering (EP 1539819B1) for its therapeutic candidates for the treatment of cancer. "We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease," Jerry Newmin, chairman and CEO of MultiCell Technologies stated in the press release. "Our technology uses the…